Get the Stockscreener App
64.25
0.53%
-0.34
Pre-market:
64.36
0.11
+0.17%
Cg Oncology Inc stock is traded at $64.25, with a volume of 644.20K.
It is down -0.53% in the last 24 hours and down -8.06% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$64.59
Open:
$64.48
24h Volume:
644.20K
Relative Volume:
0.55
Market Cap:
$5.67B
Revenue:
$5.07M
Net Income/Loss:
$-186.75M
P/E Ratio:
-27.43
EPS:
-2.3424
Net Cash Flow:
$-160.43M
1W Performance:
-4.00%
1M Performance:
-8.06%
6M Performance:
+51.39%
1Y Performance:
+149.42%
1-Day Range:
$63.57
$65.39
1-Week Range:
$61.02
$67.53
52-Week Range:
$23.65
$75.50
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 409-3700
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare CGON vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
64.25 | 5.70B | 5.07M | -186.75M | -160.43M | -2.3424 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CGON Stock Chart | CG ONCOLOGY INC (NASDAQ:CGON) - ChartMill
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference - MarketBeat
CGON: Cretostimogene advances toward broad NMIBC use with strong data, scalable manufacturing, and launch prep - TradingView
TimesSquare Capital Management LLC Decreases Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Wolfe Research initiates coverage of CG Oncology (CGON) with peer perform recommendation - MSN
CG Oncology stock initiated at Peerperform by Wolfe Research - Investing.com Nigeria
Public immunotherapy drugmaker, Lyda Hill's investment firm grow at Pegasus Park - The Business Journals
CG Oncology Initiated at Peer Perform by Wolfe Research - Moomoo
CGON Initiated Coverage by Wolfe Research -- Rating: Peer Perfor - GuruFocus
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
Bladder cancer grants back AI biomarker, price transparency research - Stock Titan
CG Oncology stock initiated at Peerperform by Wolfe Research By Investing.com - Investing.com South Africa
Wolfe Research Initiates CG Oncology(CGON.US) With Hold Rating - Moomoo
CGON Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
CG Oncology, Inc. engages with urology leaders at AUA26 to advance patient care connections - Traders Union
UBS reiterates Buy on CG Oncology stock, cites combo trial data - Investing.com Canada
CG Oncology Price Target Maintained With a $100.00/Share by HC Wainwright & Co. - Moomoo
Wedbush Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $80 - Moomoo
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Assessing CG Oncology (CGON) Valuation After Strong Phase 2 CORE 008 Cohort CX Trial Data - Sahm
Assessing CG Oncology (CGON) Valuation After Positive Phase 2 CORE-008 Bladder Cancer Data - Yahoo Finance
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108 - Moomoo
Why CG Oncology Stock Is Sliding Despite Good News - TipRanks
CG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer - Moomoo
CG Oncology reports positive phase 2 bladder cancer trial data - Investing.com UK
T. Rowe Price (CGON) reports 6.72M shares, 8.0% stake disclosed - Stock Titan
CG Oncology reports positive phase 2 bladder cancer trial data By Investing.com - Investing.com South Africa
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients - The Manila Times
RTW Investments Takes Shared 8.3% Stake in CG Oncology (CGON) - Stock Titan
Bladder cancer trial sees up to 92.3% response with new drug combo - Stock Titan
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears - MarketBeat
Truist raises CG Oncology stock price target to $82 on NMIBC data - Investing.com
Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $82 - Moomoo
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CG Oncology stock hits all-time high at 73.61 USD - Investing.com India
CG Oncology stock hits all-time high at 73.61 USD By Investing.com - Investing.com Nigeria
CG Oncology (NASDAQ:CGON) Sets New 12-Month HighStill a Buy? - MarketBeat
BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $83 - Moomoo
Number of shareholders of CG Oncology, Inc. – NASDAQ:CGON - TradingView
Q2 Earnings Estimate for CG Oncology Issued By HC Wainwright - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
CG Oncology jumps as Guggenheim starts at Buy on potential against bladder cancer - MSN
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings - Sahm
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):